Novus Biologicals Announces New AKR1B10 Antibody

Novus Biologicals recently launched a new AKR1B10 antibody (catalog # NBP1-44998).  This antibody is made to a highly specific 15 amino acid portion of human AKR1B10 and is human-specific.  This new anti-AKR1B10 antibody is useful for ELISA, immunocytochemistry/immunofluorescence, immunohistochemistry, immunoprecipitation and Western blot.  AKR1B10 expression was analyzed by Western blot in aldose reductase protein, AKR1B10 protein, 293T cells expressing aldose reductase, and HCT-8 cells expressing AKR1B10.  A band at approximately 36 kDa was visualized in AKR1B10 protein and HCT-8 cells.

This AKR1B10 antibody has been cited in four publications thus far.  In an article published in 2007 in The Journal of Biological Chemistry, Ma, et al. showed that AKR1B10 may facilitate cancer cell growth by detoxifying intracellular reactive carbonyls (PMID: 18056116). In 2008, Quinn, et al. published a paper in Chemical Research in Toxicology identifying AKR1B10 as a potential biomarker for human non-small cell lung carcinoma and as a tobacco exposure and response gene (PMID: 18788756). 

AKR1B10, short for Aldo-keto reductase family 1 member B10, is also known as ARL-1.  ARL1 is a monomeric protein that efficiently catalyzes the reduction of aromatic and aliphatic aldehydes and ketones.  AKR1B10/ARL-1 is ubiquitously expressed in many human tissues, but is highly expressed in small intestine, colon and adrenal gland. This protein is pathogenically involved in diabetic complications and has been reported that AKR1B10 is overexpressed in human tumors, such as liver, breast, and lung cancer, and may play a critical role in the development and progression of cancer.

Novus' new AKR1B10 antibody is available in two sizes (0.1mL and 25uL), and can also be requested in bulk quantities


For more information on this new AKR1B10 antibody or to inquire about product collaborations, please contact the Novus Product Development Team by calling 303-730-1950 or via e-mail at

Release Date: 
Tuesday, August 10, 2010 - 06:00